Pharmesis International Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Xuedan Wu
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.1yrs |
| CEO ownership | n/a |
| Management average tenure | 3.8yrs |
| Board average tenure | 10.2yrs |
Recent management updates
Recent updates
CEO
Xuedan Wu (61 yo)
7.1yrs
Tenure
CN¥980,394
Compensation
Mr. Xuedan Wu has been an Executive Director of Pharmesis International Ltd. since April 16, 2004 and has been its Chief Executive Officer since December 31, 2017. Mr. Wu served as the Chief Executive Offi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 7.1yrs | CN¥980.39k | no data | |
| Financial Controller | 8.6yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data |
3.8yrs
Average Tenure
Experienced Management: BFK's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 20.8yrs | CN¥980.39k | no data | |
| Non-Independent Non-Executive Chairman | 19.2yrs | no data | no data | |
| Lead Independent Director | 1.3yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
10.2yrs
Average Tenure
61yo
Average Age
Experienced Board: BFK's board of directors are seasoned and experienced ( 10.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 07:30 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmesis International Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|